An observational study of intermediate or high dose thromboprophylaxis for critically ill COVID-19 patients.

Sandra JonmarkerJacob LitorellMartin DahlbergOtto StackelbergÅsa H EverhovMårten SöderbergRebecka Rubenson-WahlinMattias GüntherJohan MårtenssonJacob HollenbergEva Joelsson-AlmMaria Cronhjort

Published in: Acta anaesthesiologica Scandinavica (2021)

A difference in 90-day mortality between intermediate and high dose thromboprophylaxis could neither be confirmed nor rejected due to a small sample size.

Keyphrases

high dose
venous thromboembolism
stem cell transplantation
low dose
direct oral anticoagulants
sars cov
cardiovascular events
risk factors
atrial fibrillation
type diabetes
cardiovascular disease
coronary artery disease